SummaryNLE · Psychiatric DisordersReal content

NLE Psychiatric Disorders — Substance Use and Addictive DisordersSummary

Summary Concepts Notes Revision Deep Dive Slides Flashcards Mistakes Cheat Mnemonics Templates

Think of this page as the pre-read for your NLE Psychiatric Disorders session on Substance Use and Addictive Disorders. PRC has built Substance Use and Addictive Disorders questions around a stable set of concepts across the last 50 items on recent papers, and this summary lays those concepts out in the order you should tackle them during self-study.

Exam context

On the NLE 2026, the Psychiatric Disorders subtest carries a "Core" weight in Professional Regulation Commission (PRC) — Board of Nursing's pattern. Substance Use and Addictive Disorders lands at position 5th out of 7 in the standard review order. Target score is 75% weighted average with no sub-test below 60%, and roughly 50 items come from Psychiatric Disorders on a typical NLE paper.

Substance Use and Addictive Disorders - Summary

Substance use and addictive disorders represent some of the most heavily tested psychiatric nursing topics on the Philippine Nursing Licensure Examination (NLE) because they demand integration of mental health nursing principles with acute, potentially life-threatening physiological emergencies. As a BSN graduate preparing for the NLE, you must master the distinction between tolerance, dependence, and addiction; recognize the distinct withdrawal timelines and presentations of different substances (particularly alcohol, opioids, stimulants, and sedative-hypnotics); apply the CIWA-Ar assessment tool; understand evidence-based pharmacological interventions; and contextualize your care within the Philippine legal framework of Republic Act 9165 (the Comprehensive Dangerous Drugs Act of 2002). This chapter synthesizes the clinical presentation, pathophysiology, nursing assessment, intervention strategies, and legal considerations essential for safe, ethical, and effective patient care in substance use disorders across primary to tertiary care settings in the Philippines.

Key Concepts

A behavioral and psychological pattern of compulsive use of a substance despite significant harm to the individual's physical health, mental health, social functioning, and occupational performance. It is characterized by loss of control over use, persistent desire or unsuccessful efforts to cut down or control use, continued use despite knowledge of harm, and a cluster of cognitive, behavioral, and physiological symptoms indicative of continued substance use despite adverse consequences. This differs from tolerance and physical dependence, which can occur even with appropriate medical use of substances (e.g., long-term pain management).

Concept

Substance Use Disorder (SUD)

Importance

Distinguishing SUD from mere tolerance or dependence is crucial for accurate diagnosis, appropriate treatment planning, and avoiding stigmatization. The nursing diagnosis often reflects 'Substance Use Disorder' or related NANDA diagnoses such as 'Ineffective Coping,' 'Risk for Injury,' or 'Disturbed Thought Processes' depending on the clinical presentation and phase of treatment. Understanding SUD as a treatable condition aligns with the biopsychosocial model and RA 9165's provision for treatment rather than purely punitive approaches.

A physiological adaptation in which the body requires increasing amounts of a substance to achieve the same effect, or the effect of the same amount diminishes over time. It reflects neuroadaptation at the cellular and molecular level — for example, receptor downregulation, changes in neurotransmitter synthesis, or altered enzyme activity. Tolerance can develop to prescribed medications (such as opioid analgesics or benzodiazepines) and does NOT inherently indicate addiction. A patient taking morphine for cancer pain who requires dose escalation over time is developing tolerance, not necessarily addiction.

Concept

Tolerance

Importance

Critical distinction for NLE: tolerance is a physiologic phenomenon, not a behavioral or psychological one. Recognizing tolerance helps nurses avoid misconstruing necessary dose adjustments in chronic illness (e.g., Parkinson's disease requiring increased dopaminergic medication) as addiction. It also explains why abrupt discontinuation of a tolerated substance often causes withdrawal — the body has adapted to the substance's presence.

A state in which the body has adapted to the continuous presence of a substance such that abrupt discontinuation produces a characteristic withdrawal syndrome — a cluster of signs and symptoms specific to the substance class. Physical dependence reflects neuroadaptation and can occur even with appropriate medical use (e.g., a patient on long-term corticosteroids or beta-blockers will experience withdrawal-like effects if stopped abruptly). Dependence is not equivalent to addiction; rather, it is a predictable physiological consequence of chronic substance use.

Concept

Physical Dependence

Importance

For NLE success: understanding physical dependence clarifies why alcohol or benzodiazepine withdrawal is medically dangerous (potentially life-threatening) even in a patient who used these substances appropriately under medical supervision. It drives the nursing imperative to never suddenly discontinue alcohol or sedative-hypnotics — gradual, supervised tapering is mandatory. Physical dependence also explains the rationale for methadone and buprenorphine maintenance in opioid use disorder: these medicines prevent withdrawal and reduce craving while allowing the person to function.

A behavioral and psychological syndrome characterized by compulsive substance use despite awareness of and harm, loss of control over use, continued use despite consequences, and strong cravings. Addiction is the mental/emotional/behavioral component of substance use disorder. It involves reward system dysregulation, where the substance becomes a dominant motivator of behavior, often at the expense of health, relationships, work, and safety. Addiction can occur with substances (alcohol, drugs) and behaviors (gambling, internet use).

Concept

Addiction

Importance

This distinction is foundational for NLE and clinical practice: addiction is not simply a consequence of tolerance or dependence — it is a distinct psychological and behavioral pattern. A person can have tolerance and dependence without addiction (e.g., someone on prescribed opioids for chronic pain). Conversely, addiction can drive drug-seeking behavior even in the absence of physical withdrawal risk (e.g., cocaine addiction causes profound psychological dependence but minimal physical withdrawal). Nurses must recognize addiction as a treatable condition deserving compassion and structured intervention, not moral judgment.

A constellation of signs and symptoms that appear when a substance on which the body is physically dependent is reduced or discontinued. Withdrawal syndromes are substance-specific and reflect the body's rebound response after losing the substance's effects. Withdrawal can range from mildly uncomfortable (opioid withdrawal) to life-threatening (alcohol and benzodiazepine withdrawal). The severity and timeline depend on the substance, duration of use, dose, individual factors (age, health status, liver/kidney function), and environmental stress.

Concept

Withdrawal Syndrome

Importance

High-yield for NLE: the withdrawal timeline for alcohol is heavily tested. Recognizing withdrawal early and managing it with evidence-based protocols (particularly benzodiazepines for alcohol/sedative-hypnotic withdrawal) prevents dangerous complications like seizures and delirium tremens. Understanding that withdrawal is a medical emergency requiring hospitalization and pharmacological support underpins appropriate prioritization of care within the Philippine healthcare system.

A reversible, substance-specific syndrome produced by recent use of a substance. Intoxication is characterized by altered mental state (euphoria, dysphoria, anxiety, impaired judgment), altered perception, impaired cognition, behavioral changes, and CNS or sympathomimetic effects. For CNS depressants (alcohol, opioids, sedatives), intoxication causes decreased consciousness, respiratory depression, and impaired motor control. For CNS stimulants (cocaine, amphetamines, methamphetamine), intoxication produces hyperarousal, agitation, dilated pupils, and cardiovascular stress.

Concept

Intoxication

Importance

Acute intoxication may present to emergency departments or community health centers. Nurses must rapidly assess airway, breathing, and circulation (the ABCs), particularly in depressant overdose where respiratory depression is immediately life-threatening. Recognizing intoxication helps differentiate substance effects from psychiatric illness or medical emergencies, guiding appropriate interventions.

Alcohol is a central nervous system depressant that enhances inhibitory neurotransmission (particularly GABA) and suppresses excitatory neurotransmission (particularly glutamate). Chronic use leads to tolerance (body adapts by upregulating excitatory pathways and downregulating inhibitory pathways). When alcohol is removed, the nervous system rebounds into a hyperexcitable state. Alcohol intoxication causes slurred speech, ataxia (incoordination), nystagmus, impaired judgment, mood lability, and in severe overdose, respiratory depression and aspiration risk. Alcohol use disorder is one of the most common substance use disorders globally and in the Philippines, with significant morbidity and mortality.

Concept

Alcohol Use Disorder and CNS Depressant Effects

Importance

Alcohol intoxication and withdrawal are the most frequently tested substance topics on the NLE. The physiological basis of withdrawal — CNS rebound excitation — explains why tremors, seizures, and delirium occur. Understanding alcohol as a depressant clarifies why overdose priority is **respiratory depression and airway protection**. The timeline and progression of withdrawal (early withdrawal → hallucinosis → seizures → delirium tremens) must be memorized for clinical decision-making.

Alcohol withdrawal is a medically emergent, potentially fatal process with a predictable timeline: (1) 6–12 hours after the last drink — early/minor withdrawal: tremors, anxiety, nausea, insomnia, sweating, tachycardia, hypertension; (2) 12–24 hours — alcoholic hallucinosis: visual or tactile hallucinations with intact orientation and reality testing (distinguishing it from full delirium); (3) 24–48 hours — withdrawal seizures ('rum fits'): generalized tonic-clonic seizures; (4) 48–72 hours — delirium tremens: severe autonomic hyperactivity (marked tachycardia, hypertension, hyperthermia, profuse diaphoresis), profound disorientation, agitation, and vivid, often terrifying hallucinations. Mortality in untreated delirium tremens can reach 5–15%. The risk factors for severe withdrawal include abrupt cessation, older age, comorbid illness, liver disease, and prior withdrawal seizures or DTs.

Concept

Alcohol Withdrawal Timeline and Progression

Importance

Absolutely essential for NLE success. This timeline is frequently tested directly and indirectly through scenario-based questions. Recognizing the phase of withdrawal allows accurate prediction of when seizures or delirium are most likely and guides treatment intensity. For example, a patient presenting 36 hours after the last drink with tremor and hallucinations is in the hallucinosis phase and is at high risk for seizures in the coming hours — preemptive benzodiazepine therapy is indicated.

Delirium tremens is the most severe manifestation of alcohol withdrawal, typically peaking 48–72 hours after the last drink. It is characterized by (1) **severe autonomic hyperactivity**: tachycardia (often >120 bpm), hypertension, fever (sometimes >39°C), and profuse diaphoresis; (2) **profound disorientation and confusion**: inability to recognize time, place, or person; (3) **agitation and restlessness**: the person may attempt to leave the bed or become combative; (4) **vivid hallucinations**: often visual (seeing objects, bugs, insects on the skin) or tactile (sensation of creeping under the skin — 'formication'). These hallucinations are frightening and the person's reality testing is severely impaired. Mortality, if untreated, is significant due to cardiac dysrhythmias, stroke, or overwhelming infection.

Concept

Delirium Tremens (DTs) — Medical Emergency

Importance

DTs is a psychiatric and medical emergency. NLE questions may ask for priority nursing interventions: (1) ensure patient and environmental safety (quiet, well-lit room to minimize sensory misperceptions; fall precautions; close observation); (2) monitor vital signs frequently (autonomic instability is lethal); (3) administer benzodiazepines as ordered; (4) institute seizure precautions; (5) maintain fluid/electrolyte balance and reorient frequently. Understanding DTs as a medical emergency — not merely a psychiatric crisis — justifies ICU-level monitoring and intensive pharmacotherapy.

Benzodiazepines (diazepam, lorazepam, chlordiazepoxide) are the **drug of choice** for managing alcohol withdrawal and delirium tremens. They work by enhancing GABAergic (inhibitory) neurotransmission, substituting for the CNS-depressant effect of alcohol and counteracting the rebound excitation. Benzodiazepines prevent seizures, reduce autonomic hyperactivity, and reverse the disorientation and hallucinations of delirium. Lorazepam is preferred in patients with liver dysfunction because it undergoes glucuronidation (less hepatic-dependent metabolism). Dosing may be fixed or **symptom-triggered** (based on CIWA-Ar score), the latter being more effective at reducing both under- and over-treatment. Benzodiazepines are **tapered**, not abruptly discontinued, to avoid rebound withdrawal.

Concept

Benzodiazepines — First-Line Treatment for Alcohol Withdrawal

Importance

Essential pharmacology for NLE. Benzodiazepines are first-line for both alcohol AND sedative-hypnotic withdrawal. Nursing considerations include: monitoring for oversedation and respiratory depression; using a symptom-triggered regimen guided by validated scales; avoiding abrupt discontinuation; and educating the patient about dependence potential if misused. The distinction between therapeutic use (alcohol withdrawal management) and abuse (benzodiazepine addiction) must be clear.

The CIWA-Ar is a validated, 10-item assessment scale that quantifies the severity of alcohol withdrawal across dimensions including nausea/vomiting, tremor, sweating, anxiety, irritability, auditory/tactile/visual disturbances, headache, and orientation. Scores range from 0–67; higher scores indicate more severe withdrawal. A CIWA-Ar score of ≤8 typically indicates minimal withdrawal risk and may not require medication, while scores >15 indicate significant withdrawal requiring pharmacotherapy. The scale is used **symptom-triggered** dosing: benzodiazepines are given based on the score rather than on a fixed schedule, allowing individualized titration and reducing both under- and over-treatment. Serial CIWA scores track withdrawal progression and treatment response.

Concept

CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised)

Importance

Symptom-triggered benzodiazepine dosing guided by CIWA-Ar reduces total benzodiazepine use, shortens hospital stay, and improves outcomes compared to fixed-schedule dosing. NLE questions may ask about the interpretation of a CIWA score and the appropriate management response. Familiarity with the scale demonstrates evidence-based practice and appropriate clinical judgment.

Chronic alcohol use impairs thiamine (vitamin B1) absorption and metabolism, causing deficiency. Thiamine is essential for carbohydrate metabolism and myelin formation. Deficiency produces **Wernicke's encephalopathy**, an acute, **reversible** neuropsychiatric emergency characterized by the classic triad: (1) confusion and disorientation, (2) ophthalmoplegia or nystagmus (eye-movement abnormalities), and (3) ataxia (gait disturbance). Untreated or inadequately treated Wernicke's progresses to **Korsakoff's psychosis** (or Korsakoff's syndrome), a chronic, largely **irreversible** condition dominated by profound short-term memory loss, inability to form new memories, and confabulation (unconsciously fabricating information to fill memory gaps). The patient may seem alert and oriented but cannot learn new information or recall recent events.

Concept

Thiamine and Wernicke-Korsakoff Syndrome

Importance

High-yield and clinically critical: **Always give thiamine BEFORE or WITH IV glucose in a suspected alcoholic patient.** Administering glucose without thiamine can consume remaining thiamine stores and trigger or worsen Wernicke's encephalopathy — this is a common NLE 'trap' question. The reversibility of Wernicke's versus the irreversibility of Korsakoff's underscores the importance of prompt thiamine replacement. Nursing interventions include recognizing early signs (confusion, nystagmus, ataxia), ensuring IV thiamine is administered, and preventing further nutritional decline with multivitamins and folic acid.

Disulfiram is a medication used to support abstinence by creating a strong negative incentive (aversion) to drinking. It works by blocking alcohol dehydrogenase, the enzyme responsible for the first step of alcohol metabolism, causing acetaldehyde to accumulate if alcohol is consumed. Acetaldehyde is toxic, producing the **disulfiram-alcohol reaction**: flushing, throbbing headache, nausea and vomiting, tachycardia, chest pain, hypotension, dyspnea, and in severe cases, cardiovascular collapse or death. The reaction can occur from even small amounts of alcohol and can persist as long as the drug remains in the system (up to ~2 weeks after discontinuation). Disulfiram requires motivated patients with informed consent and strong commitment to abstinence.

Concept

Disulfiram (Antabuse) — Aversion Therapy for Alcohol Abstinence

Importance

NLE questions test knowledge of hidden alcohol sources: patients must avoid **all alcohol**, including mouthwash, cough syrups, aftershave, cologne, vinegar-based sauces, some canned foods, and certain OTC preparations. The drug's effectiveness depends entirely on patient motivation and compliance. Nursing responsibilities include thorough patient and family teaching about the absolute need for total abstinence, possible hidden alcohol sources, the severity of the disulfiram-alcohol reaction, and the importance of informed consent. Disulfiram is not a 'cure' but a tool supporting long-term behavioral change.

Opioids (heroin, morphine, codeine, and prescription analgesics like oxycodone) are CNS and respiratory depressants that bind to opioid receptors, producing analgesia, euphoria, and respiratory depression. **Opioid intoxication/overdose** presents with the classic triad: (1) pinpoint (constricted) pupils, (2) respiratory depression (the life-threatening danger — respiratory arrest), and (3) decreased level of consciousness/coma. The antidote is **naloxone** (Narcan), an opioid antagonist that rapidly reverses respiratory depression; however, naloxone is short-acting (30–90 minutes) and must be repeated if the patient re-sedates. Naloxone can precipitate acute opioid withdrawal (see below). **Opioid withdrawal**, while intensely uncomfortable, is generally **not life-threatening** (unlike alcohol or sedative-hypnotic withdrawal). It produces dilated pupils, yawning, lacrimation (tearing), rhinorrhea (runny nose), muscle aches, abdominal cramping, diarrhea, piloerection ('cold turkey'), and strong craving. Withdrawal typically peaks 48–72 hours after the last use and subsides within 7–10 days.

Concept

Opioid Use Disorder — Intoxication, Overdose, and Withdrawal

Importance

Opioid overdose is a acute medical emergency in the Philippines and globally. Recognizing the triad and administering naloxone can be life-saving. Nursing priorities for overdose: (1) secure the airway and provide oxygen; (2) administer naloxone IV, IM, or intranasal; (3) monitor for re-sedation and repeat naloxone if needed; (4) obtain IV access and supportive care; (5) do not leave the patient unattended (risk of re-exposure to opioids after naloxone wears off). For opioid withdrawal, while not acutely dangerous, the discomfort drives relapse; medications like methadone and buprenorphine provide medically supervised withdrawal and long-term maintenance, reducing illicit use and crime.

Methadone and buprenorphine are long-acting opioid agonists (or partial agonists, in buprenorphine's case) used for medically supervised opioid withdrawal and maintenance therapy. **Methadone** is a full opioid agonist with a long half-life (24–36 hours), allowing once-daily dosing; it prevents opioid withdrawal and reduces craving. **Buprenorphine** is a partial opioid agonist with a longer half-life (24–60 hours); it also prevents withdrawal and reduces craving while having a lower overdose risk due to its partial agonist properties (ceiling effect on respiratory depression). Both medications allow patients to stabilize psychologically and socially while avoiding illicit drug use and its associated harms (crime, HIV, hepatitis C, overdose death). These medications are part of the Philippine health system's drug dependency treatment offerings, often managed through PDEA-recognized rehabilitation facilities.

Concept

Methadone and Buprenorphine — Medication-Assisted Treatment (MAT) for Opioid Use Disorder

Importance

Medication-assisted treatment (MAT) is evidence-based and reduces relapse rates and illicit opioid use. Nurses working in rehabilitation settings must understand that methadone or buprenorphine maintenance is **not enabling** — it is a legitimate medical treatment for opioid use disorder, allowing the person to function productively while avoiding the dangers of street drugs. RA 9165 recognizes treatment and rehabilitation; nurses facilitate access to these programs and educate patients and families about their benefits.

Stimulants — particularly **methamphetamine ('shabu'), cocaine, and amphetamines** — are CNS excitants that increase dopamine and norepinephrine activity, producing euphoria, hypervigilance, and increased confidence. **Intoxication** causes euphoria, agitation, dilated pupils, tachycardia, hypertension, hyperthermia (elevated body temperature), tremor, and impaired judgment. In severe intoxication or overdose: **seizures, cardiac dysrhythmias, myocardial infarction (heart attack), stroke, and acute psychosis** (with paranoia, visual/tactile hallucinations, and ideas of reference) can occur. **Methamphetamine in particular** is associated with rapid onset of psychosis, severe dental decay ('meth mouth'), skin infections from picking, and extreme behavioral dysfunction — it is a major public health and social problem in the Philippines. **Withdrawal ('crash')** produces intense fatigue, hypersomnia (sleeping too much), anhedonia (inability to feel pleasure), depression, and strong craving. The suicide risk during the crash phase is a critical concern.

Concept

Stimulant Use (Cocaine, Amphetamines, and Methamphetamine/'Shabu')

Importance

Stimulant intoxication is a medical and psychiatric emergency. Nursing interventions include: (1) manage the environment to reduce stimulation (quiet, dimly lit room); (2) monitor vital signs closely (risk of dysrhythmias and stroke); (3) assess and manage hypertension and hyperthermia (cooling measures, antihypertensives); (4) assess for psychosis and agitation, use de-escalation and PRN medications; (5) institute seizure precautions; (6) **never leave the patient alone** due to danger of self-harm. During the withdrawal/crash phase, vigilantly assess suicide risk and institute suicide precautions. Stimulant addiction has no FDA-approved medication but is managed with cognitive-behavioral therapy, supportive care, and treatment of comorbid psychiatric conditions.

Sedative-hypnotics — particularly **benzodiazepines (diazepam, lorazepam, alprazolam) and barbiturates (phenobarbital, pentobarbital)** — are CNS depressants. Like alcohol, they enhance GABAergic inhibition and suppress excitatory neurotransmission. **Withdrawal from sedative-hypnotics closely mirrors alcohol withdrawal and is equally life-threatening**, including tremors, anxiety, irritability, insomnia, autonomic hyperactivity, hallucinations, withdrawal seizures, and delirium. The timeline varies with the substance's half-life: short-acting benzodiazepines (alprazolam, lorazepam) produce rapid withdrawal (within hours to 1–2 days), while long-acting benzodiazepines (diazepam) produce slower, protracted withdrawal (days to weeks). **Barbiturate withdrawal is especially dangerous** because the margin between therapeutic and lethal dose is narrow. **Flumazenil**, a benzodiazepine antagonist, reverses overdose but is used cautiously (even with medical supervision) because it can precipitate seizures and is contraindicated in chronic benzodiazepine users.

Concept

Sedative-Hypnotic Use and Withdrawal — Life-Threatening Like Alcohol

Importance

Critical for NLE: **Never abruptly discontinue alcohol or benzodiazepines.** Withdrawal must be **gradual and supervised**. This principle applies to both alcohol and sedative-hypnotic withdrawal; benzodiazepines are used to manage withdrawal from both classes. A patient on long-term benzodiazepines for anxiety cannot simply stop — they must be tapered under medical supervision. Recognizing sedative-hypnotic withdrawal as a medical emergency and implementing symptom-triggered benzodiazepine protocols (using CIWA-Ar or a similar scale) is essential for safe care.

Recovery from substance use disorder is a long-term, multiphase process: (1) **Detoxification** — acute management of withdrawal, typically 3–10 days, in a medical or psychiatric hospital; (2) **Rehabilitation (Inpatient or Outpatient)** — typically 28–90 days or longer, focusing on education about the disorder, relapse triggers and prevention, development of healthy coping skills, psychological therapy (cognitive-behavioral therapy, motivational interviewing, group therapy), and social/occupational reintegration; (3) **Maintenance and Ongoing Support** — long-term adherence to abstinence or controlled use, ongoing therapy, peer support, and family involvement. **12-step self-help programs** — **Alcoholics Anonymous (AA), Narcotics Anonymous (NA), and Al-Anon (for family members)** — are cornerstones of recovery, emphasizing peer support, spiritual growth, and accountability. Success rates improve with longer treatment duration, family involvement, and consistent peer support.

Concept

Rehabilitation and Recovery — Long-Term Process

Importance

Nurses play a crucial role across all phases. During rehabilitation, the nurse's therapeutic stance is **firm, consistent, and non-judgmental**. Set clear limits; avoid enabling and rescuing behaviors; consistently confront denial, rationalization, and manipulation (the defense mechanisms common in addiction) while conveying genuine acceptance of the person. Encourage personal responsibility ('This is your choice; you are in control of your recovery'), identification of triggers, and development of healthy coping mechanisms. Involve family members and address codependency in family systems. Teach about relapse prevention and connect patients to community resources (AA/NA meetings, peer sponsors, PDEA rehabilitation programs).

The nurse's approach to patients with substance use disorders must balance compassion with firm boundaries. Key principles: (1) **Non-judgmental acceptance** — recognize addiction as a disease, not a moral failing; avoid stigmatizing language or tone; (2) **Firm, consistent limits** — clearly state expectations and consequences; follow through consistently; (3) **Confront denial and manipulation** — don't collude with minimization or excuses; gently but directly point out inconsistencies between stated goals and behaviors; (4) **Avoid enabling** — don't make excuses for the patient, cover up consequences, or provide financial support that facilitates substance use; (5) **Encourage responsibility** — emphasize that the patient has agency and choice in recovery; (6) **Build therapeutic alliance** — despite firm limits, convey genuine care and belief in the person's ability to recover. This stance applies across all settings: acute withdrawal units, rehabilitation centers, community health centers, and primary care.

Concept

The Therapeutic Nursing Stance in Substance Use Disorders

Importance

The nurse's stance profoundly influences treatment outcomes. Patients with substance use disorders are often demoralized, defensive, and distrustful; the nurse's consistent, firm compassion provides a corrective emotional experience. Understanding defense mechanisms (denial, rationalization, projection, displacement) helps the nurse respond therapeutically rather than becoming frustrated or judgmental. This stance aligns with RA 9165's emphasis on treatment and rehabilitation, recognizing the person as worthy of dignity and capable of change.

**RA 9165** is the primary Philippine legislation governing dangerous drugs. Key provisions relevant to nursing: (1) Created the **Dangerous Drugs Board (DDB)** as the policymaking and coordinating body for anti-drug efforts; (2) Created the **Philippine Drug Enforcement Agency (PDEA)** as the implementing and enforcement agency; (3) **Recognizes the drug-dependent person as one needing treatment and rehabilitation**, not merely punishment — it provides for voluntary submission programs, court-ordered rehabilitation, and community-based treatment; (4) Mandates **confidentiality of medical records** of drug-dependent patients undergoing treatment and rehabilitation (similar to privacy protections for other sensitive health conditions); (5) Requires **mandatory drug testing** in specified populations (e.g., new employees in regulated industries, drivers); (6) Sets penalties for importation, sale, manufacture, and possession of dangerous drugs; (7) Establishes rehabilitation facilities and programs throughout the country. The law reflects a public health approach rather than solely a criminal justice approach.

Concept

Republic Act 9165 (Comprehensive Dangerous Drugs Act of 2002) — Philippine Legal Framework

Importance

As a nurse in the Philippines, you must understand RA 9165 to practice legally and ethically. You may work in PDEA-recognized rehabilitation centers, primary health clinics, or hospitals managing acutely intoxicated or withdrawing patients. Familiarity with RA 9165 ensures you: (1) recognize rehabilitation as a legitimate treatment pathway, not a punishment workaround; (2) maintain strict confidentiality of patient records (violating confidentiality can lead to legal liability); (3) understand mandatory reporting or testing requirements if applicable; (4) educate patients and families about treatment options and legal protections. This knowledge demonstrates professional competence and ethical practice aligned with Philippine healthcare law.

Many patients with substance use disorders also have concurrent mental health conditions — depression, anxiety disorder, bipolar disorder, post-traumatic stress disorder (PTSD), or personality disorders. These co-occurring conditions (dual diagnosis or comorbidity) complicate treatment because: (1) The underlying psychiatric condition may have predisposed the person to substance use (self-medication); (2) Substance use worsens the psychiatric symptoms; (3) Withdrawal or intoxication can mimic psychiatric symptoms (e.g., stimulant intoxication mimics mania; depressant withdrawal mimics anxiety); (4) Treatment must address both conditions simultaneously. For example, an adolescent with depression who uses methamphetamine to cope requires both depression management and addiction treatment.

Concept

Dual Diagnosis (Substance Use Disorder and Co-occurring Psychiatric Illness)

Importance

NLE questions may present dual diagnosis scenarios. Nursing assessment must differentiate between substance-induced psychiatric symptoms and primary psychiatric illness — this requires careful history (when did symptoms first appear? Do they improve without the substance?), collateral information from family, and observation over time as withdrawal resolves. Treatment planning must address both conditions: psychopharmacology (antidepressants, mood stabilizers) alongside addiction treatment. Family education and peer support are especially important.

**Codependency** describes a relational pattern in family members (spouse, parent, sibling) where they become psychologically and behaviorally enmeshed in the substance-using person's disorder, often without recognizing it. Common codependent behaviors include: (1) **Enabling** — making excuses, providing financial support, covering up consequences, or facilitating the behavior ('keeping the peace'); (2) **Rescuing** — repeatedly getting the person out of trouble; (3) **Controlling** — attempting to manage the person's substance use; (4) **Neglecting own needs** — sacrificing personal health, relationships, and goals to 'help' the addicted person; (5) **Low self-esteem tied to the addicted person's behavior** — measuring worth by ability to 'fix' the problem. Families in these patterns suffer significant distress, developing anxiety, depression, and sometimes substance use themselves. **Al-Anon** is a peer support program for families of people with alcohol or drug addiction, teaching healthy boundaries and detachment.

Concept

Codependency and Family Dysfunction

Importance

Nursing interventions must include the family system. Teach family members to: (1) recognize enabling behaviors and stop them; (2) set firm, consistent boundaries; (3) allow the person to experience natural consequences of their behavior (not rescue); (4) focus on their own health and well-being (self-care is not selfish). Referral to Al-Anon or family therapy is often essential. Understanding codependency prevents the nurse from becoming drawn into enabling or rescue dynamics.

Patients with substance use disorders present with multiple nursing diagnoses across the spectrum of withdrawal, rehabilitation, and relapse prevention. Common diagnoses include: (1) **Risk for Injury** (from withdrawal seizures, disorientation, falls, or intoxication-related accidents); (2) **Risk for Thought Process Disturbance** (from intoxication or withdrawal-related confusion/hallucinations); (3) **Ineffective Coping** (reliance on substance use as a coping mechanism); (4) **Risk for Self-Directed Violence** (especially during stimulant withdrawal crash or in delirium tremens); (5) **Self-Care Deficit** (inability to maintain hygiene, nutrition, grooming due to intoxication or depression); (6) **Sleep Disturbance** (withdrawal-related insomnia or stimulant use); (7) **Social Isolation/Impaired Social Interaction** (consequence of addiction and stigma); (8) **Anxiety** (often underlying the addiction or present in withdrawal); (9) **Knowledge Deficit** (about substance effects, withdrawal, relapse prevention); (10) **Ineffective Family Processes** (codependency and family dysfunction).

Concept

NANDA Nursing Diagnoses in Substance Use Disorders

Importance

In exam questions and in clinical practice, you must formulate nursing diagnoses that accurately reflect the patient's actual or at-risk problems, determine the etiology (caused by withdrawal? intoxication? underlying psychiatric illness?), and then prioritize interventions using Maslow's hierarchy. For example, 'Risk for Injury related to altered consciousness secondary to opioid overdose' is prioritized over 'Knowledge Deficit related to relapse prevention' because safety is foundational. This nursing process approach ensures comprehensive, patient-centered care.

In patients with substance use disorders, apply Maslow's hierarchy to prioritize care across the phases of acute withdrawal, stabilization, and rehabilitation. In **acute intoxication or withdrawal**, physiological safety is paramount: airway/breathing/circulation (ABCs), seizure precautions, vital sign monitoring, prevention of falls and injury, and fluid/electrolyte management. Once the patient is physiologically stable, address **psychological safety** (therapeutic milieu, consistent boundaries, reducing fear), then **belonging and esteem** (peer support, community connection, rebuilding relationships), and finally **self-actualization** (long-term goal-setting, relapse prevention, life purpose). A patient in delirium tremens requires ICU-level physiological management before any psychological intervention; conversely, a patient in residential rehabilitation needs heavy investment in coping skills and peer support alongside basic self-care.

Concept

Maslow's Hierarchy — Prioritization in Substance Use Disorders

Importance

Exam questions test whether you can prioritize appropriately. A question might ask: 'A patient is withdrawing from alcohol and is experiencing tremors and anxiety. Which intervention is most important?' The answer is physiological stabilization (benzodiazepines, vital sign monitoring, nutrition, hydration) before intensive psychological intervention or discharge planning.

Important Points

**Tolerance ≠ Dependence ≠ Addiction**: Tolerance is physiologic (need more for same effect); dependence is physiologic (withdrawal on stopping); addiction is behavioral (compulsive use despite harm). A person can have tolerance and dependence on appropriately prescribed medication without being addicted.
**Alcohol Withdrawal Timeline** (absolutely essential for NLE): 6–12 h = tremors/anxiety/sweating; 12–24 h = hallucinations; 24–48 h = seizures; 48–72 h = delirium tremens. Later phases are life-threatening.
**Delirium Tremens is a Medical Emergency**: Severe autonomic hyperactivity (tachycardia, hypertension, fever, sweating), profound confusion, and vivid hallucinations. Mortality if untreated is 5–15%. Priority interventions: safe environment, vital sign monitoring, benzodiazepines, seizure precautions.
**Benzodiazepines are First-Line for Both Alcohol AND Sedative-Hypnotic Withdrawal**: They substitute for the CNS depressant effect and prevent seizures and delirium. Lorazepam preferred if liver is impaired. Use symptom-triggered dosing via CIWA-Ar, not fixed schedules.
**CIWA-Ar Score Guides Medication**: The Clinical Institute Withdrawal Assessment for Alcohol (revised) is a 10-item scale quantifying withdrawal severity. Score >15 indicates need for benzodiazepines. Symptom-triggered dosing reduces medication use and improves outcomes.
**GIVE THIAMINE BEFORE GLUCOSE**: In an alcoholic patient, administering IV glucose without thiamine can precipitate Wernicke's encephalopathy (confusion, nystagmus, ataxia). Wernicke's is acute and reversible with thiamine; Korsakoff's (irreversible memory loss + confabulation) develops if Wernicke's is not treated promptly.
**Disulfiram (Antabuse)**: Blocks alcohol metabolism, causing acetaldehyde accumulation. If patient drinks, severe reaction: flushing, headache, vomiting, hypotension, possible collapse. Requires complete abstinence from ALL alcohol sources (mouthwash, cough syrup, aftershave, vinegar, canned foods). Needs informed consent and strong motivation.
**Opioid Overdose Triad**: Pinpoint pupils, respiratory depression (the lethal danger), and altered consciousness. Antidote is **naloxone** (Narcan) — short-acting, can precipitate withdrawal, may need repeat dosing. Opioid withdrawal is uncomfortable but NOT life-threatening (unlike alcohol/sedative-hypnotic).
**Stimulant ('Shabu'/'Cocaine') Intoxication**: CNS excitation — dilated pupils, tachycardia, hypertension, hyperthermia, agitation. Dangers: seizures, MI, stroke, psychosis. Withdrawal ('crash'): fatigue, depression, anhedonia, strong suicide risk. No specific medication; manage environment, vitals, psychosis, and suicide risk.
**Sedative-Hypnotic Withdrawal is Life-Threatening Like Alcohol**: Can produce seizures and delirium. Never abruptly discontinue — must taper gradually under supervision. Benzodiazepines manage withdrawal from sedatives just as they do for alcohol.
**Never Abruptly Stop Alcohol or Benzodiazepines**: Both produce potentially fatal withdrawal syndromes. Always use gradual, supervised tapering.
**Therapeutic Nursing Stance**: Firm, consistent, non-judgmental. Set clear limits; avoid enabling; confront denial without shame; encourage responsibility. This balance of compassion and boundaries is essential for therapeutic alliance and recovery.
**Rehabilitation is Long-Term**: Detox (3–10 days) → Rehabilitation (28–90+ days) → Ongoing Support. AA/NA/Al-Anon are essential peer support structures. Family involvement and addressing codependency improve outcomes.
**RA 9165 (Comprehensive Dangerous Drugs Act of 2002)**: Created the **DDB** (policymaking) and **PDEA** (enforcement). Emphasizes treatment and rehabilitation, not purely punishment. Mandates **confidentiality of patient records** — violation is legally actionable. Nurses facilitate access to treatment programs and maintain ethical confidentiality.
**Dual Diagnosis**: Many substance users have concurrent psychiatric illness (depression, anxiety, PTSD, bipolar disorder). Treatment must address both simultaneously. Assess whether psychiatric symptoms are substance-induced or primary.
**Codependency**: Family members enable and rescue the addicted person, sacrificing their own health. Teach boundaries and refer to Al-Anon. Family healing is part of comprehensive recovery.
**Maslow's Hierarchy in SUD**: Acute phases prioritize physiological safety (ABCs, seizure precautions, stability). Once stable, address psychological safety, belonging, self-esteem, and long-term goals.
**NANDA Diagnoses**: Common diagnoses include Risk for Injury, Risk for Violence, Ineffective Coping, Sleep Disturbance, Knowledge Deficit. Match etiology (e.g., 'related to alcohol withdrawal seizure risk') and prioritize based on Maslow and acuity.
**Intoxication vs. Withdrawal**: Intoxication = substance present (effects); Withdrawal = substance removed (rebound). Depressants cause intoxication depression; their removal causes excitation. Stimulants cause intoxication excitation; their removal causes depression ('crash').
**Hidden Alcohol Sources for Disulfiram Patients**: Mouthwash, cough syrup, aftershave, cologne, vinegar-based salad dressings, some canned foods (especially fruits in syrup), and many OTC preparations. Patients must read all labels.

Chapter Objectives

Distinguish between tolerance, physical dependence, and addiction (substance use disorder), and explain how these concepts differ physiologically and behaviorally
Recognize and manage alcohol intoxication and its life-threatening complications, including respiratory depression
Apply the alcohol withdrawal timeline (early withdrawal, alcoholic hallucinosis, withdrawal seizures, and delirium tremens) to clinical assessment and predict when complications are most likely to occur
Identify the clinical presentation of delirium tremens, understand its mortality risk, and prioritize nursing interventions (environmental safety, vital sign monitoring, benzodiazepine administration, seizure precautions)
Explain the role of benzodiazepines as first-line therapy for alcohol and sedative-hypnotic withdrawal, and discuss why symptom-triggered dosing using the CIWA-Ar scale improves patient outcomes
Describe Wernicke-Korsakoff syndrome (Wernicke's encephalopathy and Korsakoff's psychosis), explain why thiamine must be given before glucose in alcoholic patients, and differentiate the reversible versus irreversible phases
Explain how disulfiram works as an aversion therapy for alcohol abstinence, identify all hidden sources of alcohol, and teach patients about the severe disulfiram-alcohol reaction
Recognize opioid intoxication and overdose (pinpoint pupils, respiratory depression, altered consciousness), administer naloxone appropriately, and manage opioid withdrawal using methadone, buprenorphine, and supportive care
Identify the presentation of stimulant use (including methamphetamine/'shabu'), recognize the acute dangers (seizures, dysrhythmias, myocardial infarction, psychosis), and assess suicide risk during the withdrawal crash
Understand why sedative-hypnotic withdrawal mirrors alcohol withdrawal in severity and life-threatening potential, and explain the importance of gradual supervised tapering
Apply a therapeutic, non-judgmental nursing approach to substance use disorders that firmly sets limits, avoids enabling behaviors, consistently confronts denial, and supports rehabilitation and peer support programs
Cite the key provisions of Republic Act 9165 (the Comprehensive Dangerous Drugs Act of 2002) relevant to nursing practice, including the roles of the Dangerous Drugs Board (DDB) and Philippine Drug Enforcement Agency (PDEA), treatment and rehabilitation options, and mandatory confidentiality of patient records
Integrate Maslow's hierarchy of needs and NANDA nursing diagnoses (e.g., Risk for Injury, Ineffective Coping, Disturbed Sensory Perception, Self-Care Deficit) to prioritize interventions across acute withdrawal, rehabilitation, and relapse prevention phases
Educate patients, families, and community members about relapse triggers, the dangers of abrupt cessation of alcohol and sedatives, the importance of nutrition and vitamin supplementation, and access to local and national support resources (AA, NA, Al-Anon, PDEA rehabilitation programs)

Scenario

A 52-year-old male presents to the emergency department with confusion, tremors, diaphoresis, and hallucinations. The family reports he stopped drinking 3 days ago after a 20-year history of daily alcohol use. Vital signs: BP 160/95, HR 120, Temperature 39.2°C.

Nursing Actions

Assess airway, breathing, and circulation immediately (ABCs). Secure IV access.
Place on continuous cardiac monitoring due to high risk of dysrhythmias.
Institute seizure precautions (padded bed rails, suction at bedside, tongue blade available).
Create a safe, quiet environment with low lighting to reduce sensory misperceptions and hallucinations. Have a staff member at bedside to provide reorientation and reassurance.
Administer lorazepam IV as ordered (benzodiazepine of choice — the definitive treatment for DTs). May give lorazepam rather than diazepam if liver function is impaired.
Monitor vital signs every 15–30 minutes, especially temperature (risk of neuroleptic malignant syndrome-like picture) and cardiac rhythm.
Administer thiamine IV (100 mg) with glucose if needed, but NEVER give glucose without thiamine (prevents Wernicke's).
Maintain fluid and electrolyte balance with IV fluids; monitor for hypomagnesemia (lowers seizure threshold).
Apply cooling measures (cool sponging, ice packs) if temperature >39.5°C.
Perform frequent reorientation to person, place, and time; acknowledge hallucinations without reinforcing them ('I see the walls are moving for you; let me stay here with you').
Obtain collateral history from family: duration and pattern of drinking, prior withdrawal episodes, medication allergies, comorbid medical conditions.
Once stable, begin rehabilitation planning and referral to addiction services and AA/peer support.

Clinical Context

This patient is in delirium tremens, the most severe form of alcohol withdrawal, appearing 48–72 hours after cessation. He is in medical and psychiatric danger.

Expected Outcomes

Patient stabilizes with benzodiazepines; vital signs normalize; confusion and hallucinations resolve. Patient is transferred to psychiatric/rehabilitation unit for continued care. Long-term recovery involves AA, possible disulfiram or other support medications, family involvement, and addressing underlying triggers for drinking.

Scenario

A 28-year-old female is admitted to a detoxification unit for alcohol dependence. She has a history of two prior hospitalizations for alcohol withdrawal, including one seizure. Current withdrawal symptoms: tremor, anxiety, nausea, CIWA-Ar score = 18.

Nursing Actions

Upon admission, perform detailed withdrawal history: When was the last drink? How much daily intake? Prior withdrawal episodes? History of seizures or DTs? Medical comorbidities? Liver function (jaundice, ascites)?
Administer the CIWA-Ar assessment every 1–2 hours (or per protocol) during acute withdrawal to track progression and guide medication dosing.
CIWA score of 18 indicates significant withdrawal: administer lorazepam IV/PO as ordered using symptom-triggered dosing (e.g., 2–4 mg every 30–60 min if CIWA >15, targeting score of 8–10). Avoid over-sedation but ensure adequate symptom control.
If seizure threshold is particularly high risk (prior seizures, abrupt cessation, electrolyte abnormalities), consider prophylactic benzodiazepine loading or ICU-level monitoring.
Institute seizure precautions: padded bed, suction at bedside, IV access, anticonvulsant available per protocol.
Administer thiamine 100 mg IV/IM daily for at least 3–5 days; add folic acid and multivitamin supplement.
Check baseline labs: electrolytes (especially Mg2+, K+), liver function tests (AST, ALT, GGT, albumin, PT/INR), glucose, blood alcohol level if recent.
Establish IV hydration; monitor for and correct hypomagnesemia (magnesium sulfate if Mg2+ <1.7) because hypomagnesemia lowers seizure threshold.
Perform frequent vital sign monitoring (at least every 4 hours initially, more if symptoms worsen). Watch for hypertension, tachycardia, fever, and dysrhythmias.
Provide a safe, calm environment: quiet room, soft lighting, no sudden stimuli, consistent staff. Use verbal reassurance and reorientation if hallucinations develop.
Monitor fluid intake and output; encourage oral hydration (fluids with electrolytes, thiamine-fortified drinks if available).
If nausea/vomiting develops, give antiemetics (e.g., metoclopramide or ondansetron) and monitor for aspiration risk.
After acute withdrawal phase (typically 3–7 days), transition to rehabilitation programming: group therapy, individual counseling, educational sessions on relapse prevention, family involvement, introduction to AA/peer support.
At discharge, provide prescriptions for ongoing support (e.g., naltrexone or acamprosate to reduce craving), referral to AA or PDEA rehabilitation program, outpatient mental health follow-up, and education about relapse triggers and early warning signs.

Clinical Context

This patient is at high risk for progression to seizures and delirium tremens due to prior seizure history. She requires aggressive, symptom-triggered benzodiazepine therapy to prevent dangerous complications.

Expected Outcomes

Patient successfully completes detoxification without seizures or delirium tremens. CIWA score reduces to <8 by day 3–4. Patient engages in rehabilitation, identifies relapse triggers, and establishes connection with AA or peer support. At discharge, patient has a structured aftercare plan and understanding of the importance of continued support. Long-term success depends on sustained engagement with rehabilitation and peer support.

Scenario

A 35-year-old male with alcohol use disorder is prescribed disulfiram (Antabuse) as part of his recovery plan. He is motivated to abstain and understands the medication's purpose. You are providing patient and family education.

Nursing Actions

Assess patient's readiness and motivation for using disulfiram. This medication requires informed consent and strong commitment to abstinence. If motivation is low or ambivalent, address barriers first or defer therapy.
Provide detailed education about disulfiram's mechanism: It blocks alcohol metabolism, causing acetaldehyde accumulation, which produces a severe flushing reaction if alcohol is consumed.
List explicit, comprehensive examples of hidden alcohol sources that must be avoided: mouthwash, cough syrups (especially those labeled 'alcohol-free' may contain some), aftershave, cologne, hair spray, breath freshener, vinegar-based salad dressings, cooking wines, canned fruits in syrup (especially peaches), some vanilla extracts, topical liniments, some cold medications, beer-battered foods, wine-based sauces, certain desserts (zabaglione, tiramisu), kombucha (fermented, trace alcohol), some fermented foods. Advise patient to read ALL labels and ask about ingredients.
Teach about the disulfiram-alcohol reaction: Symptoms include flushing (face and neck turning red), pounding or throbbing headache, nausea and vomiting, chest pain, tachycardia, hypotension (dizziness), dyspnea (shortness of breath), tremor, confusion, and in severe cases, cardiovascular collapse. Reaction typically begins 5–10 minutes after alcohol ingestion and can last 30 minutes to several hours.
Emphasize that **even small amounts of alcohol can trigger the reaction** (e.g., a sip of beer, a taste of wine sauce, a rinse of mouthwash).
Explain that disulfiram remains in the system for up to ~2 weeks after stopping the medication, so alcohol must be avoided during this entire period.
Advise patient to carry a card or medical alert bracelet identifying disulfiram use, in case of emergencies.
Involve the spouse/family member: Educate them to support the patient in avoiding alcohol, not to test the patient, and to understand that their own behaviors (e.g., offering a drink out of habit) must change. Discuss potential family members' codependency and refer them to Al-Anon.
Address driving: Advise patient that if a reaction occurs (especially with hypotension/dizziness), they should not drive; ensure access to safe transportation.
Emphasize that disulfiram is a **support tool**, not a cure. It works only if the patient commits to abstinence and attends therapy, support groups, and relapse prevention programs.
Reinforce that disulfiram does NOT reduce craving; psychological/behavioral interventions (AA, counseling) are essential.
Provide written materials summarizing hidden alcohol sources and the disulfiram-alcohol reaction. Ensure understanding and provide contact numbers for questions or if a reaction occurs.
Schedule follow-up appointments to monitor adherence, assess for any accidental ingestion of alcohol, and address any side effects (disulfiram can rarely cause peripheral neuropathy or hepatotoxicity).

Clinical Context

Disulfiram requires absolute adherence to alcohol abstinence and comprehensive education about hidden alcohol sources. The disulfiram-alcohol reaction can be severe and life-threatening.

Expected Outcomes

Patient and family demonstrate understanding of disulfiram mechanism, hidden alcohol sources, and the disulfiram-alcohol reaction. Patient commits to absolute abstinence and reports avoiding all alcohol sources. Family supports abstinence and recognizes their role. Patient remains engaged in AA or peer support and counseling. If accidental alcohol ingestion occurs, patient knows to seek immediate medical evaluation.

Scenario

A 19-year-old is brought to the emergency department unconscious with pinpoint pupils, slow, shallow breathing (respiratory rate 8), minimal response to stimulation. History: suspected opioid overdose (heroin). Paramedics report naloxone was not given in the field.

Nursing Actions

Immediately assess ABCs: airway patency, breathing adequacy, circulation. This patient's breathing is dangerously shallow and slow; respiratory failure is imminent.
Prepare for possible intubation and mechanical ventilation if respiratory depression worsens. Have intubation equipment, suction, and bag-mask device readily available.
Establish IV access immediately.
Administer naloxone IV as ordered (typical dose: 0.4–2 mg IV, repeated every 2–3 minutes if needed, up to 10 mg). Naloxone rapidly blocks opioid receptors, reverses respiratory depression, and restores consciousness.
As soon as naloxone is administered, the patient may 'wake up' suddenly and gasping for air. Remain calm and reassuring; the sudden arousal can be disorienting.
Monitor respiratory rate, oxygen saturation, and alertness closely. If respiratory depression recurs (because naloxone is short-acting, 30–90 min), repeat naloxone administration per protocol.
Administer supplemental oxygen to maintain oxygen saturation >94%. Use bag-mask ventilation if needed until spontaneous breathing is adequate.
Do NOT leave the patient unattended, especially in the 1–2 hours after naloxone, because re-sedation can occur if the opioid is long-acting (e.g., methadone) or if the naloxone dose was insufficient. Some naloxone requires repeat dosing every 40–60 min depending on the opioid involved.
Once the patient is conscious and stable, assess for injuries from the overdose (aspiration, falls, rhabdomyolysis if prolonged immobility).
Perform urine drug screening to confirm opioid use and rule out other substances (benzodiazepines, stimulants) that may complicate management.
Obtain detailed history from the patient or companion: What opioid was used? When? How much? Has this person overdosed before? Is there treatment for addiction?
Be aware that the patient may now be in **acute opioid withdrawal** (caused by naloxone displacing the opioid). Symptoms include yawning, lacrimation, rhinorrhea, muscle aches, cramping, diarrhea, piloerection. While uncomfortable, withdrawal is not life-threatening. Provide reassurance and supportive care.
Assess for psychiatric comorbidity (depression, anxiety, suicidal ideation) — suicidal overdose must be ruled in or out.
Once medically stable, make a **mandatory referral to addiction services** for assessment and treatment planning. Discuss medication-assisted treatment (methadone, buprenorphine) as evidence-based options.
Provide education about overdose prevention, naloxone availability, harm reduction (using with others present, not alone), and signs of overdose in companions (unresponsiveness, pinpoint pupils, gasping or apnea).
Involve case management or social work to address housing, employment, mental health services, and peer support needs.
Arrange follow-up psychiatric and addiction medicine appointments before discharge if the patient is willing. Discuss PDEA rehabilitation programs if appropriate.

Clinical Context

This is an acute, life-threatening opioid overdose. The classic triad — pinpoint pupils, respiratory depression, altered consciousness — is present. Respiratory depression is the immediate danger; naloxone is the life-saving antidote.

Expected Outcomes

Patient is successfully resuscitated with naloxone, respiratory function is restored, consciousness returns. Patient is observed for re-sedation and any complications. Once stable, patient is engaged in addiction services and treatment planning. Follow-up appointments are scheduled. Patient receives education about overdose risk, naloxone availability, and treatment options. Ideally, patient enters a medication-assisted treatment program (methadone or buprenorphine) or residential rehabilitation.

Scenario

A 23-year-old female is admitted to a psychiatric unit with acute methamphetamine intoxication. She reports using 'shabu' (methamphetamine) heavily for the past 48 hours. Current presentation: dilated pupils, extreme agitation, pressured speech, paranoid ideation ('People are following me and want to hurt me'), visual hallucinations ('I see shadows moving in the corner'), tachycardia (HR 145), hypertension (BP 175/105), temperature 38.8°C, tremor.

Nursing Actions

Ensure immediate safety: Assign a skilled staff member to remain with or near the patient at all times (1:1 observation). Reduce environmental stimulation — move to a quiet room, dim lighting, minimal staff interactions. Remove potential weapons or items that could be used to harm self or others.
Assess for agitation and violence potential. Set clear, calm, firm limits: 'I know you're frightened. I'm here to help you stay safe. Please sit on the bed. If you try to hurt yourself or me, we will need to call for help.' Use de-escalation techniques (calm, low voice; explaining procedures simply; respecting personal space).
Establish IV access and obtain baseline labs: electrolytes, glucose, cardiac enzymes (troponin) to rule out MI, CBC, urine drug screen, ECG to assess for dysrhythmias. The tachycardia and hypertension suggest significant cardiovascular stress.
Place on continuous cardiac monitoring (risk of dysrhythmias, MI).
Monitor vital signs every 15–30 minutes initially: HR, BP, temperature, respiratory rate. Methamphetamine can cause sudden cardiac or neurological emergencies.
If hypertension is severe (BP >180/110) or patient is symptomatic (severe headache, chest pain, SOB), administer antihypertensive per protocol (e.g., labetalol IV, hydralazine IV). Avoid pure beta-blockers without alpha blockade (can cause unopposed alpha effects and worsen hypertension).
If temperature is elevated (>39°C), apply cooling measures (cool sponging, ice packs to axillae and groin) and monitor closely. Hyperthermia in stimulant intoxication can lead to seizures, rhabdomyolysis, and organ failure.
**Do NOT use antipsychotics acutely if possible** — the paranoia and hallucinations will likely resolve as the methamphetamine metabolizes (within 12–24 hours for most intoxication). Antipsychotics add to the medical burden (extrapyramidal side effects, anticholinergic effects, cardiac effects). Instead, use reassurance, reorientation, and environmental control. **Benzodiazepines (lorazepam) are safer** for acute agitation and anxiety, calming the patient without adding psychotropic side effects.
Administer lorazepam 1–2 mg IV/IM every 30–60 min as needed for agitation, anxiety, or if seizures are imminent. Benzodiazepines are the safest acute management for stimulant-induced agitation.
Use frequent, calm reorientation: 'You are in a hospital. You are safe. The shadows you see are not real; they are part of the drug effect. I am here with you.'
Monitor for seizure risk. Stimulant overdose can cause seizures. Keep seizure precautions in place.
Ensure adequate hydration and nutrition. Stimulant use causes appetite suppression; patient may be malnourished and dehydrated. Provide IV fluids and encourage PO intake once stabilized.
Once the acute intoxication phase is subsiding (typically after 12–24 hours), **carefully assess for the withdrawal/'crash' phase**, which brings fatigue, depression, anhedonia, and **marked suicide risk**. Do not be falsely reassured by the patient's initial improvement; the psychological crash is dangerous.
Perform a comprehensive psychiatric assessment: history of depression, prior suicide attempts, suicidal ideation, current stressors, substance use history, family history of psychiatric illness. Assess for dual diagnosis (underlying depression or bipolar disorder).
Develop a suicide prevention plan: 1:1 observation if suicidal, safety measures (remove belts, shoelaces, sharp objects), frequent check-ins, antidepressant or mood stabilizer initiation if indicated.
Initiate addiction services consultation. Discuss medication-assisted treatment options (there is no FDA-approved medication specifically for methamphetamine, but supportive medications may help with co-occurring depression/anxiety). Connect patient with cognitive-behavioral therapy, group therapy, and NA or PDEA rehabilitation programs.
Involve family/support systems: Educate about methamphetamine's effects, relapse triggers, and ways to support recovery. Discuss family involvement in rehabilitation.
Discharge planning (once acute phase resolves): Referral to residential rehabilitation (PDEA-recognized programs), outpatient addiction medicine, psychiatric follow-up, NA meetings, case management. Provide written resources and contact information.

Clinical Context

This patient is in acute stimulant intoxication with psychotic features, significant cardiovascular and thermal stress, and paranoia-driven aggression risk. The danger is immediate: seizures, myocardial infarction, stroke, and violence.

Expected Outcomes

Acute intoxication resolves over 12–24 hours with vitals stabilizing, paranoia and hallucinations fading, and agitation controlled. Patient transitions through the withdrawal/crash phase with close suicide monitoring; no self-harm occurs. Patient recognizes the need for treatment and engages with addiction services. Short-term stay includes detoxification and psychiatric stabilization; transition to residential rehabilitation for longer-term treatment. Long-term recovery involves NA, cognitive-behavioral therapy, management of any underlying psychiatric conditions, and family involvement.

Scenario

A 45-year-old man has been on long-term benzodiazepines (alprazolam 2 mg three times daily) for anxiety for 5 years. His primary care physician decides to discontinue the medication to prevent addiction. The physician advises the patient to stop the benzodiazepine abruptly, thinking it is better to 'just stop' rather than prolong dependence.

Nursing Actions

**Immediately recognize the danger and advocate for the patient**. Contact the prescribing physician or pharmacist to alert them that abrupt benzodiazepine discontinuation will likely cause serious withdrawal.
Educate the patient (and provider if necessary) about benzodiazepine dependence: Chronic benzodiazepine use, even at prescribed doses, causes physical dependence — the body adapts. Abrupt cessation produces **withdrawal syndrome identical to alcohol withdrawal**: tremor, anxiety, insomnia, autonomic hyperactivity (tachycardia, hypertension), and dangerously, seizures and delirium.
Advocate for a **slow, supervised taper**, not abrupt cessation. Typical tapering protocols involve reducing the dose by 10–25% every 1–2 weeks, over several weeks to months. The longer the duration of benzodiazepine use and the higher the dose, the slower the taper should be.
If the patient has already begun abrupt discontinuation and is experiencing early withdrawal symptoms (anxiety, tremor, insomnia, racing heart), **immediately reinstate the benzodiazepine at the previous dose and begin a gradual taper**. Do not allow further abrupt cessation.
If the patient develops active withdrawal (seizures, delirium, severe autonomic hyperactivity), this is a medical emergency requiring hospitalization, benzodiazepine reinstatement, and intensive monitoring — similar to acute alcohol withdrawal management.
Once a tapering schedule is established, provide patient education: Explain the taper schedule and timeline. Reassure the patient that gradual tapering minimizes withdrawal symptoms. Provide written instructions and a calendar showing dose reductions. Arrange frequent follow-up (weekly or bi-weekly) to monitor for breakthrough anxiety or withdrawal symptoms.
Monitor for withdrawal symptoms during the taper: insomnia, anxiety, tremor, muscle aches, irritability, perceptual disturbances, and increased sensory sensitivity. If withdrawal symptoms emerge, slow the taper further or stabilize on the current dose before continuing the reduction.
Provide adjunctive support: Counseling to address underlying anxiety (non-pharmacological coping strategies, cognitive-behavioral therapy); sleep hygiene interventions; exercise; relaxation techniques. This helps manage anxiety symptoms as the benzodiazepine is reduced.
Consider switching to a longer-acting benzodiazepine (e.g., diazepam) during the taper if the patient is on a short-acting benzodiazepine, as longer-acting agents are associated with less severe withdrawal.
After the taper is complete and the patient is off benzodiazepines, monitor for relapse anxiety and provide ongoing mental health support. Many patients benefit from SSRIs, buspirone, or cognitive-behavioral therapy for anxiety management without benzodiazepines.
Document all patient education, warning signs, and follow-up plans. If the physician refuses to adopt a safer tapering approach and the patient is at risk, escalate through the facility's chain of command or seek ethics committee consultation.

Clinical Context

This is a **dangerous approach that violates evidence-based practice**. Abrupt discontinuation of benzodiazepines after chronic use produces life-threatening withdrawal, just as alcohol withdrawal does. The patient must be tapered gradually, not stopped abruptly.

Expected Outcomes

Patient's benzodiazepine is restarted (if abruptly discontinued) or tapered slowly under supervision. Withdrawal symptoms are minimized. Patient completes the taper without seizures or delirium. Anxiety is managed through non-benzodiazepine strategies (therapy, SSRIs, coping skills). Patient is educated about the importance of gradual tapering for any benzodiazepines in the future. The nurse's advocacy prevents a medical emergency and promotes patient safety.

Scenario

A 32-year-old woman with alcohol use disorder is discharged from a 28-day residential rehabilitation program. She completed detoxification, attended group therapy and AA meetings, and is motivated for recovery. You are providing discharge teaching and follow-up planning.

Nursing Actions

Review the discharge summary, including withdrawal history, CIWA-Ar scores, any medical complications, psychiatric diagnoses, and medications (if any: e.g., naltrexone, acamprosate, or an SSRI for depression).
Discuss the concept of **relapse prevention**: A 'slip' (one drink) is not the same as a 'relapse' (return to full addictive use). If a slip occurs, the patient should immediately seek help (call sponsor, go to an AA meeting, contact outpatient counselor) rather than viewing it as failure and giving up.
Identify personal relapse triggers in collaboration with the patient: Specific people (friends who drink), places (bars, social gatherings), situations (stress, emotional pain), or emotions (anger, loneliness, boredom). Create a plan to avoid or cope with each trigger (e.g., 'When stressed about work, I will call my sponsor or go to the gym; I will not isolate or use alcohol to cope').
Emphasize the importance of **daily AA attendance** for the first 90 days (common recommendation: '90 meetings in 90 days'). This provides accountability, peer support, and structure. Discuss the role of a sponsor (an experienced AA member who provides guidance and emotional support).
Provide written information about local AA and NA meetings, times, locations, and phone numbers. If the patient is religious, mention SMART Recovery, LifeRing, or other secular peer support options if preferred.
Ensure the patient has scheduled **outpatient follow-up appointments**: (1) addiction medicine or psychiatry (every 1–2 weeks initially, then monthly); (2) individual therapy or counseling (weekly); (3) medical/primary care (baseline health screening after withdrawal). Provide appointment cards or have the patient call to confirm appointments before leaving the facility.
Discuss **prescribed medications for relapse support**: naltrexone (blocks opioid reward system, reduces craving for alcohol) or acamprosate (reduces protracted withdrawal symptoms and supports abstinence). Explain how each works, expected side effects, importance of adherence. If disulfiram is considered, review absolute alcohol avoidance and hidden alcohol sources.
Address **medical management**: Ensure adequate thiamine, folate, and multivitamins to repair nutritional deficits. Discuss screening for liver disease (cirrhosis), pancreatitis, neuropathy, and GI complications. Schedule follow-up labs in 4–6 weeks.
If **psychiatric comorbidity** is present (depression, anxiety, trauma), discuss the importance of treating these alongside addiction. Medication and therapy are essential. A patient with untreated depression will struggle with relapse prevention.
Discuss **family involvement**: Encourage the patient to engage family in her recovery (if safe and healthy). Provide information about Al-Anon for family members to learn about codependency, boundaries, and their own healing. If the family dynamic is chaotic or enabling, recommend family therapy.
Provide education about **self-care and healthy living**: Sleep hygiene, regular exercise (endorphins improve mood naturally), balanced nutrition, stress management techniques (yoga, meditation, journaling), and avoiding isolation. These support long-term recovery.
Address **work/employment and financial stability**: Discuss return-to-work plans, financial management, and vocational counseling if needed. Stable employment and housing are protective factors against relapse.
Educate about **warning signs of relapse**: Increasing isolation, stopped attending meetings, increased irritability or mood changes, insomnia, fantasizing about using, hanging around people who use, or thinking 'I can just have one.' Teach the patient to recognize these and seek help immediately.
Provide **crisis resources**: National SAMHSA Helpline (1-800-662-4357), local crisis hotlines, emergency department numbers, and the patient's therapist's emergency contact. Emphasize that relapse is not a failure — it's a signal to intensify support.
For patients in the Philippines, provide information about PDEA rehabilitation programs, local NA/AA chapters, and government health facilities offering addiction services.
Arrange a **follow-up phone call 1 week after discharge** to check in, reinforce learning, assess for early relapse risk, and troubleshoot any barriers to accessing outpatient care.
Document thoroughly: discharge instructions, appointments scheduled, patient verbalization of understanding, referrals made, and the patient's stated commitment to recovery.

Clinical Context

Discharge is a high-risk period — relapse is common in the first few weeks after leaving a structured environment. The nurse's role is to solidify the patient's recovery plans, educate about relapse triggers, and connect her with community supports.

Expected Outcomes

Patient is discharged with a clear, actionable recovery plan. She understands relapse triggers and has coping strategies in place. She has committed to attending AA meetings daily, has a sponsor or is planning to get one, and has outpatient appointments scheduled. She understands the importance of medication, therapy, and self-care. Follow-up contact at 1 week shows engagement with her recovery plan. Long-term success depends on her continued adherence to the plan, peer support, and willingness to address underlying issues (trauma, depression) that contributed to her drinking.

Loading diagram…

In summary

Substance use and addictive disorders represent a complex intersection of neurophysiology, psychology, behavior, and social determinants that requires comprehensive, evidence-based nursing care. As a BSN graduate preparing for the Philippine Nursing Licensure Examination, you must master the distinction between tolerance, physical dependence, and addiction — three separate but related phenomena that are frequently confused in clinical scenarios. The alcohol withdrawal timeline (early withdrawal at 6–12 hours; hallucinosis at 12–24 hours; seizures at 24–48 hours; delirium tremens at 48–72 hours) is a high-yield, directly testable concept that underpins understanding of why early benzodiazepine therapy is life-saving. The CIWA-Ar assessment, symptom-triggered benzodiazepine dosing, thiamine replacement (always before glucose to prevent Wernicke's encephalopathy), and safe seizure precautions form the core of acute withdrawal management across alcohol and sedative-hypnotic use. Understanding opioid overdose (the lethal triad of pinpoint pupils, respiratory depression, and altered consciousness) and naloxone's rapid reversal is essential for emergency response. Recognizing stimulant intoxication (particularly methamphetamine/'shabu') and the dangerous withdrawal crash with elevated suicide risk requires vigilant assessment and supportive management. Your therapeutic nursing stance — firm, consistent, non-judgmental — prevents enabling and supports the patient's journey toward recovery. Integration of rehabilitation (therapy, peer support through AA/NA/Al-Anon, life skills rebuilding), medication-assisted treatment (methadone, buprenorphine, disulfiram), and family involvement addresses the multifactorial nature of addiction. Finally, understanding Republic Act 9165 (the Comprehensive Dangerous Drugs Act of 2002) contextualizes your practice within the Philippine legal and healthcare system, emphasizing treatment and rehabilitation, mandatory confidentiality of patient records, and the coordinated efforts of the Dangerous Drugs Board (DDB) and Philippine Drug Enforcement Agency (PDEA). By integrating all these elements — physiological knowledge, psychiatric assessment, pharmacotherapy, behavioral intervention, legal awareness, and genuine compassion — you will be prepared to provide comprehensive, safe, and effective nursing care to patients with substance use disorders, preventing needless suffering and supporting genuine recovery.

Next steps

To consolidate your learning and prepare for NLE success, engage in the following activities: (1) **Create flashcards** with the alcohol withdrawal timeline, benzodiazepine protocols, and pharmacological agents used in each substance class — test yourself daily until these are automatic. (2) **Work through scenario-based questions** involving acute intoxication, withdrawal management, and discharge planning; practice prioritizing interventions using Maslow's hierarchy and recognizing NANDA nursing diagnoses. (3) **Review RA 9165 in detail** — access the full text if possible, and understand the roles of the DDB and PDEA in your practice context. (4) **Study the CIWA-Ar scale** — download a sample assessment tool and practice scoring to understand how different symptom clusters translate to medication decisions. (5) **Engage with case studies** involving dual diagnosis (e.g., methamphetamine use with underlying bipolar disorder; alcohol use disorder with depression) and work through comprehensive nursing care plans. (6) **Attend or review recordings of AA or NA meetings** (many are public) to understand peer support dynamics and recovery language — this deepens your appreciation for the human experience of addiction and recovery beyond clinical definitions. (7) **Discuss substance use scenarios with peers or mentors**, including ethical dilemmas (e.g., a patient who wants to use disulfiram but family history suggests compliance risk; a pregnant patient with opioid use disorder weighing methadone maintenance) to develop clinical judgment. (8) **Review relevant Philippine health policy and statistics** on drug use and treatment outcomes in the Philippines to ground your understanding in local context. (9) **Practice calculating benzodiazepine doses and taper schedules** to ensure mathematical competency. (10) **Reflect on personal biases and attitudes** toward people with substance use disorders — addressing implicit bias improves the therapeutic relationship and clinical effectiveness. By engaging thoroughly with this content, you will be well-prepared for NLE questions on substance use disorders and, more importantly, ready to provide compassionate, competent care to vulnerable patients across the Philippine healthcare system.

Previous chapter

Personality, Somatic, and Eating Disorders

Next chapter

Cognitive, Organic, and Neurodevelopmental Disorders

Ready to practise for the NLE 2026?

Super Tutor's AI review plan adapts to your weak areas and builds a weekly practice schedule around your target NLE exam date.

Start free See the full NLE guide NLE preparation guide

← Back to Psychiatric Disorders hub